Navigation Links
52 minority scientists receive travel fellowships to Experimental Biology 2008
Date:3/18/2008

BETHESDA, MD (March 18, 2008) One of the nations oldest and most respected non-profit science organizations will provide more than $86,000 in travel fellowships to underrepresented minority students and scientists to attend the Experimental Biology conference in San Diego, CA, April 5-9. The American Physiological Society (APS), which administers the program, has announced that 52 fellows will receive the travel awards.

APS administers the program with financial support from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and the National Institute of General Medical Sciences (NIGMS). Both NIDDK and NIGMS are part of the National Institutes of Health.

The APS Minority Travel Fellowship Program is designed to encourage more students from minority groups that are underrepresented in science to become scientists and remain in the field. African-American, Hispanic, Native American and Pacific Islander undergraduate, graduate and post-doctoral students and faculty are eligible for the fellowships. The APS has awarded travel fellowships to approximately 500 minority students and faculty since 1987, when the program began.

In addition to paying travel and registration costs, each fellow is paired with an established researcher, an APS member who is usually in the same research area as the student. More than 60 APS members volunteer each year to be mentors. A number of former minority travel fellows -- now established researchers with their own graduate students -- serve as mentors themselves.

The program provides many career networking opportunities. The mentor introduces the fellow to other established scientists at the conference, and the fellows meet other minority students at an orientation and reception for current and past travel fellows. APS also invites fellows to career workshops, sessions on special skills development, and other special sessions during the conference.

Past fellows hav
'/>"/>

Contact: Brooke Bruthers
bbruthers@the-aps.org
301-634-7226
American Physiological Society
Source:Eurekalert

0

GOOD

Page: 1 2 3

Related medicine news :

1. Nyer Medical Group Completes Acquisition of Minority Interest in Pharmacy Chain Subsidiary; Former Minority Shareholders Invest in Nyer Medical Group and Sign 3-Year Employment Agreements
2. First Group of Minority Nurse Faculty Scholars Selected by the Johnson & Johnson Campaign for Nursings Future and AACN
3. HLTH Corporation Sells its Minority Interest in Emdeon Business Services to General Atlantic and Hellman & Friedman for $575 Million
4. National survey shows minority children experience multiple disparities in health care
5. IAC Acquires a Minority Stake in The HealthCentral Network
6. NCAE Encourages Minority Youth and Their Families to Go-for Health and Fitness
7. Turnaround Partners Sells Minority Ownership in Interactive Nutrition to Natural Nutrition
8. Nyer Medical Group Reaches Agreement to Acquire Minority Interest in Pharmacy Chain Subsidiary
9. The Endocrine Society Publishes White Paper Calling for Greater Minority Participation in Clinical Research
10. Kentucky Pharmacists Event Urging Senate Minority Leader McConnell to Fix Flawed Medicaid Drug Reimbursement Rule
11. It takes a community to address cancer disparities among underserved minority populations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/26/2008)...an farm, FDA announces , , FRIDAY, July...ering the first big clue in the nationwide salmone...ay that tainted jalapeno peppers had been definiti...d and Drug Administration gave the all-clear to ja...tes, but warned consumers to avoid any raw jalapen...
(Date:7/25/2008)...ter & Olsen LLP has filed a,class action lawsuit a...,"Company") (Nasdaq: ARTC ) and certain of its of...District of Texas on behalf of all persons or,enti...m January 24, 2008,through July 18, 2008 (the "Com... or entities who purchased call options or sold pu...
(Date:7/25/2008)...inancial results -, LAVAL, QC, July 25 /PRNewswir...DSS) today announced that it will host a conferenc...scuss its second quarter 2008,financial results. L...cial,results via news release at approximately 7:0...ll by telephone, dial 416-646-3095 or,1-800-814-48...
(Date:7/25/2008)...FirstCall/ -- Thoratec,Corporation (Nasdaq: THOR ...atory support therapies to save, support and resto...port its operating results for the second,quarter ...uly 31., The company will hold a conference call ...ivities to all interested parties at 1:30 p.m.,Pa...
Breaking Medicine News(10 mins):Health News:Mexican Peppers ID'd as Salmonella Culprits 2Health News:Mexican Peppers ID'd as Salmonella Culprits 3Health News:Klafter & Olsen LLP Announces That It Has Filed a Class Action Lawsuit Against ArthroCare Corporation on Behalf of Common Stock Holders and Certain Traders in ArthroCare Options 2Health News:Klafter & Olsen LLP Announces That It Has Filed a Class Action Lawsuit Against ArthroCare Corporation on Behalf of Common Stock Holders and Certain Traders in ArthroCare Options 3Health News:Labopharm to host conference call Friday, August 8, 2008 at 8:30 A.M. (ET) 2Health News:Thoratec Schedules Second Quarter 2008 Conference Call, Webcast 2
...skin of males than females. // Researchers at the ...of hairless mice to ultraviolet rays from a sun la...e WebMD, The mice underwent eight- to 10-minute ta...a week for six months. That was enough to give bot...
...of nutrition for many people around the globe. Thi...veral forms, it is the key ingredient for cooking ...ter just round the corner an animal rights group i...aign on Wednesday urging people not to eat eggs. &...
...ession for that ‘bronzed and beautiful’ look. But ...researchers. // According to a report published i... Health, the increases in people going in for tann...s is particularly so when considered in the light ...
...nts in the US, the public libraries in that countr...s. // In bad weather -- hot, cold, or wet -- most...ces. The local shelters push them out onto the s...g and, even when the weather is good, they are alr...
Other Medicine News:Health News:Sultans of Suntans Warned 2Health News:Public Libraries Turning into Shelters for the Homeless in the US 2
(Date:7/24/2008)...l/ -- MacroChem Corporation (OTC,Bulletin Board: M... trial,involving 37 patients who completed a 48-we...ety study of EcoNail, a topical antifungal,lacquer... The composite,primary efficacy endpoint of the tr...gy (negative fungal culture and negative KOH) and ...
(Date:7/23/2008)...uly print edition of Clinical ...23 /- A Roche Diagnostics-sponsored,p...type natriuretic peptide,(NT-proBNP) confirms the ...on in predicting the risk of cardiovascular advers...oidal anti-inflammatory drugs of,the COX inhibitor...
(Date:7/23/2008)...Pharma Inc., a company developing,breakthrough mol...mography,(PET) market, announced positive Phase I ...racer for myocardial perfusion imaging. BFPET is,F...plete Phase I clinical,development., BFPET is a P...w in the,heart (myocardial perfusion). Myocardial ...
(Date:7/23/2008).../ -- Dendreon Corporation,(Nasdaq: DNDN ) today a...toring Committee (IDMC) to review in October 2008 ...to the Company,s Phase 3 IMPACT (IMmunotherapy,for...D9902B) clinical trial,of PROVENGE(R) (sipuleucel-...ve cellular immunotherapy for the treatment of adv...
Breaking Medicine Technology:MacroChem Announces Phase 2 Data for EcoNail(R) in the Treatment of Onychomycosis 2MacroChem Announces Phase 2 Data for EcoNail(R) in the Treatment of Onychomycosis 3MacroChem Announces Phase 2 Data for EcoNail(R) in the Treatment of Onychomycosis 4MacroChem Announces Phase 2 Data for EcoNail(R) in the Treatment of Onychomycosis 5Study Reveals Potential for NT-proBNP as a Marker to Predict Cardiovascular Risks From Anti-Inflammatory Drugs 2Study Reveals Potential for NT-proBNP as a Marker to Predict Cardiovascular Risks From Anti-Inflammatory Drugs 3Study Reveals Potential for NT-proBNP as a Marker to Predict Cardiovascular Risks From Anti-Inflammatory Drugs 4FluoroPharma Announces Positive Phase I Safety Results for BFPET(TM), Myocardial Perfusion Imaging (MPI) Tracer for Positron Emission Tomography (PET) 2FluoroPharma Announces Positive Phase I Safety Results for BFPET(TM), Myocardial Perfusion Imaging (MPI) Tracer for Positron Emission Tomography (PET) 3Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October 2Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October 3Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October 4Study Finds PCI Safe Effective Despite Off Site Cardiac Surgery 1620 1Study Finds PCI Safe Effective Despite Off Site Cardiac Surgery 1620 2Study Finds PCI Safe Effective Despite Off Site Cardiac Surgery 1620 3Study Finds PCI Safe Effective Despite Off Site Cardiac Surgery 1620 4Study Results Show Investigational Drug Prasugrel Cuts Risk of Stent Related Clots by More than Half Versus Clopidogrel 1617 1Study Results Show Investigational Drug Prasugrel Cuts Risk of Stent Related Clots by More than Half Versus Clopidogrel 1617 2Study Results Show Investigational Drug Prasugrel Cuts Risk of Stent Related Clots by More than Half Versus Clopidogrel 1617 3Study Results Show Investigational Drug Prasugrel Cuts Risk of Stent Related Clots by More than Half Versus Clopidogrel 1617 4Study Results Show Investigational Drug Prasugrel Cuts Risk of Stent Related Clots by More than Half Versus Clopidogrel 1617 5Study Results Show Investigational Drug Prasugrel Cuts Risk of Stent Related Clots by More than Half Versus Clopidogrel 1617 6Study Results Show Investigational Drug Prasugrel Cuts Risk of Stent Related Clots by More than Half Versus Clopidogrel 1617 7New Drug Shows Promise in Use With Coronary Stents 15457 1New Drug Shows Promise in Use With Coronary Stents 15457 2Motorola Biometric Identification System Selected by West Virginia State Police 2660 1Motorola Biometric Identification System Selected by West Virginia State Police 2660 2
...Serial Outpatient Infusion Study in Patients with,...he American,College of Cardiology 56th Annual Scie...RLEANS, March 25, 2007,/PRNewswire/ -- Scios Inc. ...Phase 2 study of nesiritide (NATRECOR(R)) showed a...te of death and,cardiorenal hospitalization at 12 ...
....J., March 25, 2007 /PRNewswire/ -- Once-daily,dos...tolvaptan, a,vasopressin receptor antagonist, was ... of acutely decompensated heart failure (ADHF),in ... without an,adverse effect on their long-term surv...ort- and long-term analyses of the,international l...
Other Medicine Technology:Scios Announces Results From Exploratory Nesiritide Study Providing,Important New Renal and Mortality Safety Data with a Neutral Effect,on the Primary Endpoint 2Scios Announces Results From Exploratory Nesiritide Study Providing,Important New Renal and Mortality Safety Data with a Neutral Effect,on the Primary Endpoint 3Scios Announces Results From Exploratory Nesiritide Study Providing,Important New Renal and Mortality Safety Data with a Neutral Effect,on the Primary Endpoint 4Scios Announces Results From Exploratory Nesiritide Study Providing,Important New Renal and Mortality Safety Data with a Neutral Effect,on the Primary Endpoint 5Scios Announces Results From Exploratory Nesiritide Study Providing,Important New Renal and Mortality Safety Data with a Neutral Effect,on the Primary Endpoint 6Scios Announces Results From Exploratory Nesiritide Study Providing,Important New Renal and Mortality Safety Data with a Neutral Effect,on the Primary Endpoint 7Everest Data on Short- and Long-Term Use of Otsuka's,Investigational Novel Treatment, Tolvaptan, Published in Journal of,the American Medical Association and Featured in ACC's Late,Breaking Clinical Trials 2Everest Data on Short- and Long-Term Use of Otsuka's,Investigational Novel Treatment, Tolvaptan, Published in Journal of,the American Medical Association and Featured in ACC's Late,Breaking Clinical Trials 3Everest Data on Short- and Long-Term Use of Otsuka's,Investigational Novel Treatment, Tolvaptan, Published in Journal of,the American Medical Association and Featured in ACC's Late,Breaking Clinical Trials 4Everest Data on Short- and Long-Term Use of Otsuka's,Investigational Novel Treatment, Tolvaptan, Published in Journal of,the American Medical Association and Featured in ACC's Late,Breaking Clinical Trials 5Everest Data on Short- and Long-Term Use of Otsuka's,Investigational Novel Treatment, Tolvaptan, Published in Journal of,the American Medical Association and Featured in ACC's Late,Breaking Clinical Trials 6Everest Data on Short- and Long-Term Use of Otsuka's,Investigational Novel Treatment, Tolvaptan, Published in Journal of,the American Medical Association and Featured in ACC's Late,Breaking Clinical Trials 7
Smooth colibri tip; In Titanium.
Fine .12mm Tip With 5mm Platform; In Titanium.
Curved Shaft with 5mm Platform; 1x2, 0.12 mm teeth; In Titanium.
0.3mm tips; 9.5mm from tips to cross action; in Titanium.
Medicine Products: